📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 2.7.4 — Summary of Clinical Safety (OBX-319)

Document ID: M274
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH M4E(R2) / E3

The clinical safety of OBX-319 — a humanized IgG1 anti-CD19 × anti-CD20 bispecific monoclonal antibody produced by Chinese hamster ovary (CHO) cell culture and administered subcutaneously — is summarised principally from the pivotal 52-week Phase 3 study OBX319-301, conducted in adults with moderate-to-severe active Systemic Lupus Erythematosus (SLE) on background standard-of-care. Because OBX-319 acts by simultaneous engagement of CD19 and CD20 to achieve near-complete peripheral B-cell depletion, the safety evaluation was directed at the identified and potential risks characteristic of B-cell–depleting therapy: serious and opportunistic infections, hypogammaglobulinaemia, injection/administration reactions, and immunogenicity. Consistent with ICH S6(R1), the sole pharmacologically relevant nonclinical species was the cynomolgus monkey (no rodent target cross-reactivity); standard small-molecule safety modules — genotoxicity, carcinogenicity, and a dedicated hERG/thorough-QT evaluation — are not warranted for a monoclonal antibody of this class and are therefore not part of the safety data package. Exposure–response and immunogenicity are detailed in M2.7.2; nonclinical safety in M2.6.

2.7.4.1 Extent of Exposure

Randomized N = 480 across 3 arms.

Safety analysis set and treatment exposure — All 480 randomized subjects received at least one subcutaneous dose of study treatment and are included in the Safety Analysis Set: 320 received OBX-319 (162 at the High dose, 158 at the Low dose) and 160 received placebo, each on background standard-of-care. Study drug was administered subcutaneously throughout the 52-week double-blind period.

Duration of exposure — Exposure was balanced across arms, with the large majority of subjects in each group exposed for the full 52-week interval. This provides an adequate duration to characterise the on-treatment safety of continuous, near-complete B-cell depletion, including the lagged infection and immunoglobulin effects expected of the class.

Arm	Treated (N)	Completed Week 52	Discontinued
OBX-319 High	162	145	17
OBX-319 Low	158	145	13
Placebo	160	150	10

Overall, 440 subjects (145 High, 145 Low, 150 Placebo) completed the 52-week double-blind treatment period and 40 (17 High, 13 Low, 10 Placebo) discontinued treatment before Week 52; completion rates were high and comparable across arms.

Pharmacodynamic exposure (target engagement) — On both active arms, subcutaneous OBX-319 produced near-complete depletion of circulating CD19+ B cells, from approximately 210 cells/µL at baseline to approximately 7 cells/µL, sustained through Week 52; peripheral B-cell counts were essentially unchanged on placebo. Because OBX-319 exhibits target-mediated drug disposition (TMDD), systemic exposure is non-linear at low concentrations and is governed in part by the depleting B-cell mass. This profound and durable on-target pharmacology frames the anticipated safety risks (infection susceptibility, immunoglobulin decline) discussed below.

2.7.4.2 Adverse Events

Overall adverse event summary — The proportion of subjects reporting at least one treatment-emergent adverse event (TEAE) was similar across all three arms (78/162 High, 74/158 Low, 78/160 Placebo), with no excess on the active groups relative to placebo. The majority of TEAEs were mild to moderate in severity.

Arm	N	≥1 TEAE	SAE	Deaths	Discontinued
OBX-319 High	162	78	2	1	17
OBX-319 Low	158	74	1	0	13
Placebo	160	78	1	0	10

Most frequent adverse events (subjects, by arm)

Preferred term	OBX-319 High	OBX-319 Low	Placebo
Upper respiratory tract infection	25	18	13
Urinary tract infection	16	14	14
Nasopharyngitis	11	14	16
Headache	11	11	16
Lupus nephritis flare	4	8	16
Injection site reaction	14	7	6

Interpretation of common events — The most frequently reported events were infections of the upper respiratory and urinary tracts and nasopharyngitis, consistent with the expected profile of a B-cell–depleting agent; these were predominantly mild-to-moderate and non-serious. Lupus nephritis flare was reported more frequently on placebo (16) than on OBX-319 Low (8) or High (4), a gradient that reflects disease control by active treatment rather than a drug-related adverse effect. Injection site reactions showed a dose-ordered incidence (14 High, 7 Low, 6 Placebo), in keeping with subcutaneous administration; these were generally mild, transient, and localised, and did not lead to treatment discontinuation.

Infections (important identified risk) — Serious and opportunistic infections are the principal identified risk of B-cell depletion. The overall infection burden was dominated by non-serious upper respiratory and urinary tract infections and nasopharyngitis; the incidence of serious infection was low and is described in Section 2.7.4.3. No cases of progressive multifocal leukoencephalopathy, tuberculosis reactivation, or hepatitis B virus reactivation were reported over the 52-week period; screening for latent tuberculosis and hepatitis B was performed at entry, and live/attenuated vaccines were prohibited during treatment. Surveillance for serious and opportunistic infection is a central element of the risk-management strategy.

Immunoglobulins and hypogammaglobulinaemia (important identified risk) — Consistent with the mechanism, mean serum immunoglobulin concentrations (most notably IgM, with smaller changes in IgG) declined modestly from baseline on the active arms while remaining, for most subjects, at or near the normal range; a minority developed immunoglobulin values below the lower limit of normal without an associated increase in serious infection over the controlled period. Immunoglobulins are monitored as part of routine safety follow-up, and persistent hypogammaglobulinaemia is carried as an important identified risk.

Injection/administration reactions — Local injection site reactions were the most characteristic administration-related events (see table above); systemic administration and hypersensitivity reactions were infrequent and non-serious, and no anaphylaxis was reported. This pattern is consistent with subcutaneous delivery of a humanized IgG1.

Haematology — Absolute neutrophil counts were monitored given the potential for cytopenias, including late-onset neutropenia, with B-cell–depleting antibodies. No clinically significant neutropenia or associated serious infection was identified.

Immunogenicity — Anti-drug antibodies (binding and neutralising) were assessed using a tiered, validated assay strategy (screening, confirmatory, titre, and neutralising-antibody tiers). Observed immunogenicity was low-level and did not have a clinically meaningful impact on exposure, efficacy, or safety, consistent with a humanized IgG1. Because immunogenicity can alter the exposure of a TMDD-governed antibody, ADA status is integrated into the population PK and safety analyses; detailed results are provided in M2.7.2 and the immunogenicity summary report.

Laboratory, vital signs, and cardiac safety — Beyond the intended on-target reduction in CD19+ B cells (~210 → ~7 cells/µL) and the associated fall in anti-dsDNA antibodies and normalisation of complement C3/C4 among responders, no new or clinically important laboratory, vital-sign, or electrocardiographic signal was identified. Consistent with ICH guidance for biotechnology-derived products, a dedicated thorough-QT study and hERG assessment are not warranted for a monoclonal antibody, and no cardiac repolarisation signal was observed on routine ECG monitoring.

Malignancy — No clustering of malignant events was observed over the 52-week controlled period. Given the immunomodulatory mechanism, malignancy is retained as a potential long-term risk to be further characterised in continued treatment and post-marketing follow-up.

2.7.4.3 Deaths, SAEs, Discontinuations

Deaths — One death occurred, in the OBX-319 High arm (1 High, 0 Low, 0 Placebo). Consistent with the identified infection risk of profound B-cell depletion, the fatal event was a serious infection in a subject with active lupus and background immunosuppression; it was reviewed by the investigator and sponsor and managed with standard care. No fatal events occurred on the OBX-319 Low or placebo arms.

Serious adverse events — Serious adverse events were infrequent and comparable across arms (2 High, 1 Low, 1 Placebo), with no dose-related pattern. Serious events were predominantly serious infections, in line with the pharmacology of B-cell depletion; one of the two serious events in the High arm had the fatal outcome described above, and the remaining serious events resolved with treatment. No unexpected serious event attributable to the anti-CD19 × anti-CD20 bispecific mechanism was identified.

Discontinuations — Forty subjects discontinued study treatment before Week 52 (17 High, 13 Low, 10 Placebo), corresponding to high completion in all arms (145/162 High, 145/158 Low, 150/160 Placebo). Discontinuations did not show a treatment-related pattern indicative of a specific tolerability concern; reasons included adverse events, withdrawal of consent, and lack of efficacy, the last being more relevant on placebo.

Overall safety conclusion — Over the 52-week double-blind period, OBX-319 was generally well tolerated at both dose levels. The overall TEAE incidence was comparable to placebo, serious adverse events and deaths were infrequent and without a meaningful dose-related pattern, and the adverse-event profile was consistent with the known class effects of B-cell–depleting therapy — chiefly infections, injection site reactions, and modest immunoglobulin decline — each of which is addressed by the routine monitoring and risk-management strategy. No safety signal specific to the active treatment or to the bispecific mechanism was identified.

ICH M4E(R2) §5.3.5; ICH E3; ICH S6(R1); ICH E2A. Cross-references: M2.7.2 (clinical pharmacology, immunogenicity), M2.6 (nonclinical summaries), M2.5.6 (benefit–risk).